Extended Data Figure 4|. Unique genomic features alone do not identify long term survivors.

a, Overall survival of patients with tumors harboring greater or lesser than the median number of neoantigens (Neoantigen^Hi/Low), CD3-CD8 double positive cells (CD3-CD8^Hi/Low), polyclonality (Polyclonal^Hi/Low), mutations (Mutation^Hi/Low), and CD4 single positive cells (CD4^Hi/Low). b, Oncoprint demonstrating no difference in the frequency of oncogenic driver mutations in short and long term tumors. c, No difference in the number of nonsynonymous, missense, and immunogenic mutations (neoantigens) in short and long term PDAC tumors. d, Overall survival stratified by mutations in ARID1A, KRAS^Q61H, RBM10, and MLL-related genes (MLL, MLL2, MLL3, MLL5). Horizontal bars, median values. n = biologically independent samples in individual patients. P-values were determined using log-rank test (a, d).